Cavintonum

General characteristics. Structure:

Active ingredient: Vinpocetine of 5 mg

Excipients:
Ascorbic acid, sodium disulphite, tartaric acid, benzyl alcohol, sorbitol, water for injections.

Pharmacological properties:

Pharmacodynamics. Improves metabolism of a brain, increasing consumption of glucose and oxygen brain tissue. Increases resistance of neurons to a hypoxia; strengthening glucose transport to a brain, through a blood-brain barrier; transfers process of disintegration of glucose to energetically more economical, aerobic way; selectively blocks Sa 2+/dependent phosphodiesterase (PDE); increases levels of adenosinemonophosphate (AMF) and a cyclic guanozinmonofosfat (tsGMF) of a brain. Increases concentration of ATP in brain tissues; strengthens exchange of noradrenaline and serotonin of a brain; stimulates the ascending branch of noradrenergichesky system, has antioxidant effect.
Reduces aggregation of thrombocytes and the increased viscosity of blood; increases the deforming ability of erythrocytes and blocks utilization by adenosine erythrocytes; promotes increase in return of oxygen erythrocytes. Strengthens neuroprotective action of adenosine.
Increases a cerebral blood stream; reduces resistance of vessels of a brain without essential change of indicators of system blood circulation (arterial pressure, minute volume, heart rate, the general peripheral resistance). Not only does not render effect of "burglarizing", but also strengthens blood supply, first of all, in ischemic sites of a brain with low, perfusion.

Pharmacokinetics. Therapeutic concentration in plasma - 10-20 ng/ml. At parenteral administration distribution volume - 5.3 l/kg. The elimination half-life makes 4.74-5 h. Easily gets through gistogematichesky barriers (including a blood-brain barrier).
It is removed with kidneys and through digestive tract in the ratio 3:2.

Indications to use:

Neurology: reduction of expressiveness of neurologic and mental symptoms at various forms of a circulatory unefficiency of a brain (an ischemic stroke, a recovery stage of a hemorrhagic stroke, an effect of the had stroke; tranzitorny ischemic attack; vascular dementia; vertebrobazilyarny insufficiency; atherosclerosis of vessels of a brain; posttraumatic and hypertensive encephalopathy).

Ophthalmology: chronic vascular diseases of a choroid and retina of an eye (e.g. thrombosis (occlusion) of the central artery or vein of a retina).
For treatment of decrease in hearing of perceptual type, Menyer's disease, an idiopathic sonitus.

Route of administration and doses:

Drug is intended for intravenous drop infusion, to enter slowly (speed of infusion should not exceed 80 thaws/min.)!
It is forbidden to enter intramusculary and intravenously without cultivation!
For preparation of infusion it is possible to use the normal saline solution or solutions containing a dextrose (Salsol, Ringer, Rindexum, Reomakrodeks). Infusion solution with Cavintonum should be used in the first 3 h after preparation.

Usual initial daily dose: 20 mg (2 amp.) in 500 ml of infusion solution. Depending on portability, within 2-3 days it is possible to increase a dose no more than to 1 mg/kg/day. The average duration of treatment is 10-14 days.
Average daily dose at the body weight of 70 kg - 50 mg (5 amp. in 500 ml of infusion solution).
At diseases of a liver and kidneys of dose adjustment it is not required.
Upon termination of a course of intravenous therapy it is recommended to continue treatment by the tablets Kavinton® forte (according to 1 tab. 3 times a day) or Kavinton® (according to 2 tab. 3 times a day).

Features of use:

Existence of a syndrome of the prolonged interval of QT and administration of drugs causing lengthening of an interval of QT demands periodic control of an ECG.
Kavintona® infusion solution contains sorbitol (160 mg / 2 ml) therefore in the presence of a diabetes mellitus it is necessary to control periodically sugar level in blood.
In case of intolerance of fructose or deficit 1,6 diphosphatases of fructose it is necessary to avoid use of a Vinpocetine.
Effect of drug on ability to drive the car: data on influence of the Vinpocetine on ability to driving and working mechanisms, no.

Side effects:

By-effects against the background of use of drug came to light seldom.
From cardiovascular system: change of an ECG (ST depression, lengthening of an interval of QT); tachycardia, premature ventricular contraction, however, existence of a causal relationship is not proved since in natural population these symptoms are observed with the same frequency; change of arterial pressure (decrease is more often), erubescence, phlebitis.
From the central nervous system: sleep disorders (sleeplessness, the increased drowsiness), dizziness, a headache, the general weakness (these symptoms can be manifestations of a basic disease).
From system of digestion: dryness in a mouth, nausea, heartburn.
Others: allergic reactions of skin; the increased sweating.

Interaction with other medicines:

Interaction is not observed at simultaneous use with β-blockers ((((((((((хлоранолол, Pindololum), Clopamidum, glibenclamide, digoxin, atsenokumaroly or Hydrochlorthiazidum.
In rare instances simultaneous use with and - methyl-finish singing is followed by some strengthening of hypotensive effect, at use of such combination regular control of arterial pressure is necessary.
Despite the absence of the data confirming a possibility of interaction it is recommended to show care at co-administration with drugs of the central nervous, antiarrhythmic action.

Concentrate of Kavintona® for preparation of solution for infusions and heparin - are chemically incompatible therefore their introduction in one infusional mix is forbidden, however, it is possible to carry out treatment by anticoagulants and a Vinpocetine at the same time.
The concentrate of Kavintona® for preparation of solution for infusions is incompatible with the infusion solutions containing amino acid therefore they cannot be used for cultivation of Cavintonum.

Contraindications:

Acute phase of a hemorrhagic stroke, severe form of coronary heart disease, heavy arrhythmias and the known hypersensitivity to a Vinpocetine.
Pregnancy, lactation period.
Children up to 18 years (in connection with insufficiency of data).

Overdose:

Treatment at overdose: gastric lavage, reception of absorbent carbon, symptomatic therapy.

Storage conditions:

At a temperature of 15-30 °C, in the place protected from light.
To store in places unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Concentrate for preparation of solution for infusions, 5 mg/ml.
On 2 ml, 5 ml or 10 ml of drug in ampoules from brown glass I of a hydrolytic class with a point for a break of white color. On 5 ampoules in the plastic pallet.
2 ml and 5 ml: on 2 plastic pallets in a cardboard pack with the application instruction.
10 ml: on 1 plastic pallet in a cardboard pack with the application instruction.